Strong international growth, but Type 2 retention stumbles
- Q2 2026 revenue reached $802 million, growing 22.7% on a constant currency basis.
- International Omnipod revenue grew 33% in constant currency, leading management to raise overseas guidance.
- U.S. growth guidance was cut to 17% to 19% because new Type 2 diabetes users are struggling with early retention.
- Omnipod sales make up almost all of the total revenue, keeping the business tied to one core platform.
A tale of two markets
Insulet is growing fast in overseas markets. International revenue jumped 33% in the second quarter of 2026 on a constant currency basis. That strong demand caused management to raise its international growth forecast for the year.
The U.S. market is facing a new hurdle. The company cut its domestic growth guidance because people with Type 2 diabetes are dropping off the platform in their first 90 days. Management admits they misjudged how hard it would be to onboard this new patient group.
The public case rests on execution. If new sales incentives and better patient support fix the early retention drop, the massive Type 2 market can still drive years of growth. If these users prove too hard or expensive to keep, U.S. growth will stay under pressure.
A medical razor and blades model
Insulet sells the Omnipod platform for insulin delivery. Users wear a small tubeless pump called a Pod, which delivers insulin and is replaced after up to three days. That creates repeat revenue instead of mostly one-time device sales.
The pay-as-you-go model lowers the upfront cost for patients and insurers. It can also make the product easier to try than a traditional pump with a larger initial device cost.
The moat comes from tubeless design, patents, insurance coverage, and habit. Diabetes devices become part of daily life, so switching can be hard once a patient, doctor, and payor are used to a system.
The weak point is concentration. Omnipod was 99.6% of Q1 2026 revenue. If quality, supply, reimbursement, or competition hurts Omnipod, there is little else in the company big enough to offset it.
Omnipod 5 carries the company
Omnipod 5
This is Insulet's flagship automated insulin delivery system. It connects with third-party continuous glucose monitors, which are sensors that track blood sugar through the day.
Type 2 diabetes indication
The FDA cleared Omnipod 5 for adults with Type 2 diabetes in 2024. This segment is a major growth driver, generating over 40% of new customer starts in recent quarters.
Sensor integrations
Insulet is adding more sensor choice, including Dexcom G7 and Abbott FreeStyle Libre 2 Plus in various markets, opening up the platform to more patients.
Omnipod Discover
Launched in 2026, Omnipod Discover is a data and reporting platform for Omnipod 5 users, caregivers, and health care providers. It can help users and doctors see blood sugar patterns.
Omnipod DASH and Classic Omnipod
These older generations support existing users, but the company is shifting attention to Omnipod 5. Classic Omnipod is being phased out.
Drug Delivery
This small line uses Pod technology for partners, including Amgen's Neulasta Onpro kit. It makes up less than one percent of overall revenue.
Nearly all revenue is Omnipod
The mix uses revenue for the three months ended March 31, 2026. Omnipod was 99.6% of revenue, split between U.S. Omnipod at 67.7% and International Omnipod at 31.9%.
What could break the story
Type 2 retention drop-off
High impact · High oddsInsulet cut its U.S. revenue guidance because Type 2 diabetes users showed lower retention and utilization in their first 90 days. If the company cannot fix this onboarding friction, the lifetime value of these new customers will be lower than expected.
Repeat Pod quality issue
High impact · Medium oddsIn March 2026, Insulet started a voluntary medical device correction for certain Omnipod 5 lots because a manufacturing defect could cause insulin leakage. The event shows how hard it is to make complex disposable medical devices at scale.
Single-platform dependence
High impact · Medium oddsOmnipod drives almost all of the total revenue. This focus helps Insulet scale, but it also means a reimbursement change, supply problem, or competitor win can hit the whole company.
Tariff exemption risk
Medium impact · Medium oddsA U.S. Department of Commerce Section 232 investigation began in September 2025 and could remove current tariff exemptions for certain medical devices, including insulin pumps. That could raise costs and pressure margins.
In one breath
What does Insulet sell?
Insulet sells Omnipod, a tubeless insulin pump system. The main product is Omnipod 5, which can adjust insulin delivery using data from a continuous glucose monitor.
Why are Pods recurring revenue?
Each Pod is disposable and is used for up to three days before replacement. That means the company earns repeat sales as active users keep ordering Pods.
Why did Insulet cut U.S. guidance in Q2 2026?
Management noted that new Type 2 diabetes users are struggling with onboarding in their first 90 days. This lower retention caused the company to cut its full-year U.S. revenue growth guidance.
Why does Type 2 diabetes matter for Insulet?
The Type 2 market is much larger than the traditional pump market for Type 1 diabetes. Omnipod 5 was cleared for adults with Type 2 diabetes in 2024, representing a massive new growth avenue.
